Menactra
Brand Name: Menactra®
Composition: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine / Vaccin polysaccharidique contre le méningocoque (groupes A, C, Y et W-135) conjugué à l’anatoxine diphtérique
Format: Injectable solution (1 dose vial / 1 flacon dose)
Administration: Intramuscular use / Voie intramuscular
Manufacturer: Sanofi Pasteur
Product Description
Medical Info
Menactra® is a premium, quadrivalent conjugate vaccine manufactured by Sanofi Pasteur to protect against invasive meningococcal disease. It safely immunizes individuals against four major serogroups of Neisseria meningitidis—A, C, Y, and W-135—by chemically bonding their capsule polysaccharides to a diphtheria toxoid protein carrier. This sophisticated configuration enhances the immune system’s memory response for sustained, long-term defense. Supplied as a single-dose injectable solution for intramuscular administration, Menactra® is clinically essential for adolescents, travelers, and at-risk populations to effectively prevent highly dangerous, fast-acting bacterial infections like meningitis and meningococcemia.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
